Interferon alpha for chronic myeloid leukemia relapsing after allogeneic bone marrow transplantation
Juan Luis Steegmann(Hospital Universitario de La Princesa), J M Fernández-Rañada(Hospital Universitario de La Princesa), Enrique Granados(Spanish Society of Hematology and Hemotherapy), Lourdes Vázquez, Á Figuera(Hospital Universitario de La Princesa), Rafael de la Cámara(Hospital Universitario de La Princesa), Ján Tomáš(Hospital Universitario de La Princesa), Luis Casado(Hospital Universitario de La Princesa), Maria Teresa Ferrò(Hospital Universitario Ramón y Cajal), César Sanz-Rodrı́guez(Merck Biopharma Co., Ltd. (Japan)), R. Arranz(Hospital Universitario de La Princesa), Adrían Alegre(Hospital Universitario de La Princesa)
Cited by 32
Related Papers
A New Prognostic Score for Survival of Patients With Chronic Myeloid Leukemia Treated With Interferon Alfa Writing Committee for the Collaborative CML Prognostic Factors Project Group
|JNCI Journal of the National Cancer Institute|1998|820
European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia
|Leukemia|2016|473
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure
|New England Journal of Medicine|2019|464